

Name of registered patient advocacy

group:

below.

pCODR Patient Advocacy Group Conflict of Interest Declarations

ľ	Name of drug and indication under review: Nivolumab
Cc	onflict of Interest Declarations
Sec	ction A: Payment Received
1.	Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
	X Yes No
	If no, please go to Section B
2.	What form of payment did this patient advocacy group receive? (Check all that apply.)
	 □ Operating X Program Funding (e.g., Funds website) □ Royalties □ Research/educational grants □ Gifts □ Sponsorship of Events □ Honoraria □ Other, please specify:
3.	Please provide the names of companies and organizations and the amounts of the payments in the box below.
	Bristol Myers Squibb Canada - \$
Sec	ction B: Holdings or Other Interests
\$10	s this patient advocacy group received or is it in possession of stocks or options of more than 0,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in e drug under review? If yes, please list in the table below.
ſ	No
Sed	ction C: Affiliations, personal or commercial relationships
Do	es this patient advocacy group have personal or commercial relationships either with a drug or

Melanoma Network of Canada

health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table

No. None

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Signature: Annua Cys Name: Annette Cyr Date:

26/08/2015